Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
STAAR Surgical Co. (STAA) – Form 4 insider filing
On 18 June 2025, non-employee director Dr. Elizabeth Yeu received her annual board equity package:
- Restricted Stock Units (RSUs): 5,341 – each RSU converts to one common share upon vesting.
- Stock Options: 9,708 – exercise price $16.85, expire 17 June 2035.
On 18 June 2025, STAAR Surgical Company (STAA) convened its 2025 Annual Meeting of Shareholders with a strong quorum of 44,746,693 shares (≈90% of the 49.5 million outstanding).
Director elections (Proposal 1): All six nominees were re-elected for terms expiring at the 2026 meeting. Shareholder support ranged from 96%–99% of votes cast, with Arthur C. Butcher receiving 41.1 million “For” votes and Lilian Y. Zhou receiving 41.9 million.
Auditor ratification (Proposal 2): BDO USA, P.C. was confirmed as independent auditor for fiscal 2025 with 44,463,071 “For” votes (≈99%), only 273,085 “Against,” and 10,537 abstentions.
Say-on-Pay advisory vote (Proposal 3): Compensation of named executive officers was approved on a non-binding basis, receiving 41,130,690 “For” votes (≈97.5%), 1,049,897 “Against,” 24,667 abstentions, and 2,541,439 broker non-votes.
No other matters were brought before the meeting, and no substantive changes to corporate strategy or financial guidance were disclosed.